AA
ALDX icon

AlphaCentric Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

AlphaCentric Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.7K Buy
37,120
+2,208
+6% +$9.67K 0.06% 236
2025
Q4 		$181K Buy
+34,912
New +$179K 0.18% 154
2024
Q4 		$234K Buy
+46,913
New +$241K 0.23% 106

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCentric Advisors's ALDX Position: Q1 2026 in Review

AlphaCentric Advisors increased its Aldeyra Therapeutics (ALDX) stake by 6.3% in Q1 2026, buying an estimated $9.67K and bringing the position to 37,120 shares worth $62.7K. The position accounts for 0.06% of the portfolio, ranked #236.

AlphaCentric Advisors first reported a position in ALDX in Q4 2024 and has held it in 3 quarters since. The position peaked at $234K in Q4 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • AlphaCentric Advisors held 37,120 shares of Aldeyra Therapeutics worth $62.7K as of Q1 2026.
  • AlphaCentric Advisors bought 2,208 Aldeyra Therapeutics shares in Q1 2026, an estimated $9.67K.
  • Aldeyra Therapeutics made up 0.06% of AlphaCentric Advisors's portfolio in Q1 2026, its #236 holding.
  • AlphaCentric Advisors first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Aldeyra Therapeutics position peaked at $234K in Q4 2024.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.